Fujifilm ramps up production of flu drug Avigan as possible COVID-19 treatment

Fujifilm Diosynth Biotechnologies in Texas
Fujifilm, which has been pouring money into its manufacturing network in Japan and elsewhere, says has restarted production of Avignan, an influenza drug that is produced only in special circumstances. (Fujifilm)

Fujifilm says it is prepared to offer Avigan to any country that wants to try it as a potential treatment for COVID-19. But even as it has restarted production, the Japanese drugmaker feels compelled to set the record straight about the influenza drug.  

“Avigan has never been distributed in the market and is not available at hospitals and pharmacies in Japan or overseas,” it said in an announcement.  

RELATED:Guinea approves Fujifilm's Avigan to treat early Ebola cases

The drug, developed by Fujifilm unit Toyama Chemical, was approved in 2014 as an influenza treatment but only to be used if other treatments prove ineffective against a novel or re-emerging influenza virus. 

The Japanese company issued the clarification Friday as interest in the drug builds. That follows reports that clinical trials of the drug in China showed it effective against COVID-19. Over the weekend, Japanese Prime Minister Shinzo Abe said the government would begin trials of the drug on COVID-19 in cooperation with other countries and ramp up production with the aim of a quick approval, the Nikkei Asia Review reports.   

RELATED: Fujifilm in Avigan API license with Zhejiang Hisun Pharmaceuticals

Fujifilm pointed out in its announcement that favipiravir, the active pharmaceutical ingredient in the tablet, has a “mechanism of action that prevents the propagation of viruses…that might  have an antiviral effect on the novel coronavirus." COVID-19 is classified into the same type (single-stranded RNA virus) as influenza virus. To test that possibility, clinical trials are underway to seek “clear evidence of the drug's efficacy and safety,” Fujifilm said.

Avigan has been rolled out before, including in 2015 against Ebola and in 2016 for avian influenza. At the time, the company made this prophetic observation:

"The need to develop new drugs for treating influenza has come amidst mounting concerns--in recent years that avian influenza viruses could mutate into a new type of virus, capable of human-to-human transmission. Such a mutation could potentially trigger a pandemic."

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.